GSK stock adds a liver candidate to its pipeline
Published on 10/07/2026 at 13:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
GSK stock was last quoted at GBp 1,769.50 on the London Stock Exchange on October 7, 2026, up 0.23 percent for the session. The latest pipeline step came on September 30, when GSK selected a hepatology candidate from its Wave Life Sciences collaboration for further development.
Pipeline gains a liver candidate
According to StockTitan on September 30, 2026, the candidate uses Wave's SpiNA design GalNAc-siRNA technology and will move into GSK's development pipeline. The selection triggers a USD 12 million milestone payment to Wave, while three additional collaboration programs advance toward possible candidate selection.
The financial upside is conditional rather than immediate. Wave is eligible for USD 330 million to USD 375 million in development, launch and commercial milestones for each collaboration program, plus tiered royalties on net sales, according to StockTitan.
Quarterly growth sets the base
GSK's most recent reported quarter also delivered a measurable comparison. The July 28, 2026 release showed revenue of GBP 8.41 billion against a forecast of GBP 8.26 billion, while earnings per share came in at 0.51 against 0.46, according to Investing.com.
That combination gives investors two separate measures to track: the near-term earnings base and the longer-dated pipeline conversion. The Wave program is still a development asset, so its commercial value depends on later clinical, regulatory and launch milestones rather than the USD 12 million selection payment alone.
Analysts see room above the quote
MarketBeat reports a Hold consensus from 8 analysts, with an average 12-month target of GBp 2,064.38. The highest target is GBp 2,500 and the lowest is GBp 1,500, placing the average target 16.93 percent above the GBp 1,765.50 reference price used by the consensus page.
On the London Stock Exchange, GSK's October 7, 2026 quote stood 22.47 percent below its 52-week high of GBp 2,282.00 and 11.15 percent above its 52-week low of GBp 1,592.00. The stock's market position therefore reflects both pipeline expectations and a valuation debate that remains visible in the analyst range.
GSK stock trades below its yearly high
GSK stock was last at GBp 1,769.50 on the London Stock Exchange on October 7, 2026, with a 52-week range of GBp 1,592.00 to GBp 2,282.00. The 0.23 percent session gain and the distance from the yearly high frame the market reaction to the new pipeline asset without turning a development candidate into a commercial product.
GSK stock facts
- Company: GSK plc
- ISIN: GB00BN7SWP63
- Ticker: GSK
- Trading venue: London Stock Exchange
- Price (as of October 7, 2026): GBp 1,769.50
- 52-week range: GBp 1,592.00-2,282.00
- Sector / Industry: Healthcare / Pharmaceuticals
